UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Christof Vulsteke (BE) on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa . For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts , Spotify , EAU YouTube channel .
